Polaris Group - Product Pipeline Review - 2012 - Our pharmaceuticals report, "Polaris Group - Product Pipeline Review - 2012" provides data on the Polaris Group's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, Polaris Group's corporate website, SEC filings, investor presentations and featured press releases, both from Polaris Group and industry-specific third party sources, put together by our team.
Scope
- Polaris Group - Brief Polaris Group overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Polaris Group human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Polaris Group with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Polaris Group's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Polaris Group's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Polaris Group in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Polaris Group's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Polaris Group.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Polaris Group and identify potential opportunities in those areas.
Table of Contents
Table of Contents
List of Tables
List of Figures
Polaris Group Snapshot
Polaris Group Overview
Key Information
Key Facts
Polaris Group – Research and Development Overview
Key Therapeutic Areas
Polaris Group – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Polaris Group – Pipeline Products Glance
Polaris Group – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Polaris Group Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Polaris Group – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Polaris Group – Drug Profiles
ADI-PEG 20
Product Description
Mechanism of Action
R&D Progress
ADI-PEG-20 + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Histidase-PEG 20
Product Description
Mechanism of Action
R&D Progress
PX-228
Product Description
Mechanism of Action
R&D Progress
TNF-PEG 20
Product Description
Mechanism of Action
R&D Progress
Uricase-PEG 20
Product Description
Mechanism of Action
R&D Progress
Polaris Group – Pipeline Analysis
Polaris Group – Pipeline Products by Therapeutic Class
Polaris Group – Pipeline Products by Route of Administration
Polaris Group – Pipeline Products By Mechanism of Action
Polaris Group – Recent Pipeline Updates
Polaris Group – Locations And Subsidiaries
Head Office
Polaris Group, Recent Developments
Polaris Group- Press Release
Jun 12, 2012: Polaris's ADI-PEG 20 Demonstrates Potential Anticancer Activity In Various Metastatic Sarcomas And Bladder Cancers
Feb 28, 2012: Polaris Group Doses First Patient In Phase I Clinical Trial Of ADI-PEG 20 In Pediatric Patients
Jan 10, 2012: Polaris Doses First Patient In Phase I Clinical Trial Of ADI-PEG 20 In Combination With Docetaxel In Advanced Solid Tumors
Nov 02, 2009: EnzymeRx Launches Clinical Study Of Uricase-PEG 20
Sep 25, 2009: EnzymeRx Announces Its IND For Uricase-PEG 20 Becomes Effective
Financial Deals Landscape
Polaris Group, Deals Summary
Polaris Group, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Polaris Acquires Intellectual Property Rights Of ADI-PEG 20 From Phoenix Pharmacologics
Polaris Acquires Intellectual Property Rights Of Uricase-PEG 20 From Phoenix Pharmacologics
Polaris Acquires Intellectual Property Rights To Biotherapeutic Agents From Phoenix Pharmacologics
Partnerships
Ludwig Institute Enters Into Co-Development Agreement With Polaris For ADI-PEG 20
Acquisition
Polaris Acquires TDW Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Polaris Group, Key Information
Polaris Group, Key Facts
Polaris Group – Pipeline by Indication, 2012
Polaris Group – Pipeline by Stage of Development, 2012
Polaris Group – Monotherapy Products in Pipeline, 2012
Polaris Group – Combination Treatment Modalities in Pipeline, 2012
Polaris Group – Phase III, 2012
Polaris Group – Phase II, 2012
Polaris Group – Phase I, 2012
Polaris Group – Pre-Clinical, 2012
Polaris Group – Pipeline By Therapeutic Class, 2012
Polaris Group – Pipeline By Route of Administration, 2012
Polaris Group – Pipeline Products By Mechanism of Action, 2012
Polaris Group – Recent Pipeline Updates, 2012
Polaris Group, Deals Summary
Polaris Acquires Intellectual Property Rights Of ADI-PEG 20 From Phoenix Pharmacologics
Polaris Acquires Intellectual Property Rights Of Uricase-PEG 20 From Phoenix Pharmacologics
Polaris Acquires Intellectual Property Rights To Biotherapeutic Agents From Phoenix Pharmacologics
Ludwig Institute Enters Into Co-Development Agreement With Polaris For ADI-PEG 20
Polaris Acquires TDW Pharma
List of Figures
Polaris Group – Pipeline by Indication, 2012
Polaris Group – Pipeline by Stage of Development, 2012
Polaris Group – Monotherapy Products in Pipeline, 2012
Polaris Group – Combination Treatment Modalities in Pipeline, 2012
Polaris Group – Pipeline By Route of Administration, 2012
Polaris Group - Pipeline Products By Mechanism of Action, 2012 28